US basedUS hosted
Desks
$2 / month

Comment and reply across TML.

Start or manage membership

Most pulsed

Advertisement Sinscents Bad Intentions. Great Candles.

Latest from other desks

tml.the modern leap
Health / Medical Research

FDA Approves Giredestrant Combination for Advanced Breast Cancer

The Food and Drug Administration approved giredestrant (Wilserdly, Genentech) in combination with everolimus on Monday, November 16, 2026, for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer, as detected by an FDA-authorized test, whose disease recurred during or after adjuvant endocrine therapy or progressed on at least one endocrine regimen in the metastatic setting. Giredestrant is an oral estrogen receptor antagonist.

A woman receives a mammogram (archive). Photo: Rhoda Baer, National Cancer Institute, via Wikimedia Commons.
Summary

The approval turns on a mutation test. Wilserdly's first label reaches only patients whose tumors carry an ESR1 mutation and whose cancer already came back on endocrine therapy, which makes the authorized test part of the treatment decision.

Tap a passage. React to the part that matters.

The Food and Drug Administration approved giredestrant, sold as Wilserdly by Genentech, in combination with everolimus on Monday, November 16, 2026, for adults with estrogen receptor (ER)-positive, HER2-negative breast cancer that's locally advanced or metastatic and carries a mutation in the estrogen receptor 1 gene, ESR1. The approval covers patients whose disease recurred during or after they completed endocrine-based adjuvant therapy, or who progressed on at least one endocrine-based regimen in the metastatic setting, and the ESR1 mutation has to be detected by an FDA-authorized test.

Giredestrant is an oral estrogen receptor antagonist, part of the class known as selective estrogen receptor degraders, or SERDs. ER-positive breast cancer grows in response to estrogen signaling, and endocrine therapy works by cutting that signal off. ESR1 mutations are one of the ways tumors escape: the receptor changes shape so it stays active even when standard endocrine drugs are present. A drug built to degrade the receptor itself is aimed at exactly that escape route, which is why the label is gated on the mutation rather than offered to every ER-positive patient.

The evidence behind the combination comes from the Phase III evERA Breast Cancer study, a randomized, open-label, multicenter trial registered as NCT05306340, which compared giredestrant plus everolimus against standard endocrine therapy plus everolimus in patients previously treated with a CDK4/6 inhibitor and endocrine therapy. Genentech reported that the combination reduced the risk of disease progression or death by 62% in the ESR1-mutated population and by 44% in the overall trial population, with results published in The New England Journal of Medicine in October 2026. Overall survival data were still immature at publication.

The timing is earlier than the calendar the company had been working to. Genentech's application for the combination had been accepted with an FDA decision expected in December 2026, and a separate application for giredestrant as adjuvant treatment in early-stage ER-positive, HER2-negative breast cancer is under priority review with a goal date of November 30, 2026. Monday's approval settles the advanced-disease question first. It doesn't cover early-stage disease, and it doesn't cover ER-positive tumors without an ESR1 mutation.

For patients, the practical sequence now runs through the test. An oncologist treating advanced ER-positive, HER2-negative disease that has already moved through endocrine therapy needs an FDA-authorized ESR1 result before Wilserdly fits the label, and the drug is taken with everolimus, an established targeted therapy with its own monitoring burden. The approval adds an oral option at the point where the standard endocrine playbook has stopped working, and it makes mutation testing at progression a step that decides a real treatment, not a research question.

The approval also lands in a crowded month for the drug's maker. Genentech is a member of the Roche Group, and giredestrant is the centerpiece of a five-trial Phase III program that spans early-stage and advanced disease, including the lidERA study in the adjuvant setting and the persevERA study in earlier metastatic treatment. Monday's decision is the program's first approval, and it's the narrowest version of the idea: one mutation, one combination partner, one point in the treatment sequence where standard endocrine therapy has already failed. Wider labels, if they come, will arrive on the strength of the trials still in line.

The conversation

A little more perspective.

Reading is free. Verified members can comment and reply for $2 a month.

The conversation.

Loading comments…

Keep your curiosity going.

Some links here are affiliate links. If you buy through one, we might make a commission — it never changes what you pay. As an Amazon Associate I earn from qualifying purchases.